Volume 13, Number 4Review ArticlesReview of the Literature: PCA3 for Prostate Cancer Risk Assessment and PrognosticationDiagnosis ReviewAlan W PartinStacy LoebProstate cancer antigen 3 (PCA3) is a novel urine-based prostate cancer biomarker that has recently been studied extensively for the prediction of prostate biopsy results and treatment outcomes. Numerous studies have demonstrated that urinary PCA3 scores are predictive of prostate cancer detection on both initial and repeat biopsy. There is conflicting evidence on the relationship between PCA3 with aggressive tumor features and treatment outcomes. This article reviews the current evidence on PCA3 as a marker for prostate cancer detection and prognosis. [Rev Urol. 2011;13(4):e191-e195 doi: 10.3909/riu0539] © 2011 MedReviews®, LLCProstate cancerProstatectomyProstate cancer antigen 3Risk assessment